TY  - JOUR
AU  - Ponce Aix, Santiago
AU  - Talbot, Denis
AU  - Govindan, Ramaswamy
AU  - Dols, Manuel Cobo
AU  - Postmus, Pieter E
AU  - Lewanski, Conrad
AU  - Bennouna, Jaafar
AU  - Fischer, Juergen R
AU  - Juan-Vidal, Oscar
AU  - Stewart, David J
AU  - Ardizzoni, Andrea
AU  - Bhore, Rafia
AU  - Wolfsteiner, Marianne
AU  - Reck, Martin
AU  - Ong, Teng Jin
AU  - Morgensztern, Daniel
PY  - 2020
DO  - 10.2217/fon-2019-0796
UR  - http://hdl.handle.net/10668/15304
T2  - Future oncology (London, England)
AB  - Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL...
LA  - en
KW  - EORTC QLQ-C30
KW  - EQ-5D-5L
KW  - durvalumab
KW  - lung cancer symptom scale
KW  - nab-paclitaxel
KW  - non-small cell lung cancer
KW  - quality of life
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Albumins
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel
KW  - Quality of Life
KW  - Retreatment
KW  - Treatment Outcome
TI  - Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
TY  - research article
VL  - 16
ER  -